ATP02

Proteinase 3 (cANCA)

Native - Human Neutrophils

Alternate Names:

Myeloblastin | p29 | AGP7

Uniprot IDs:
mRNA RefSeq:
Protein RefSeq:

Want to see pricing and place an order?

Register and then log-in

Have an enquiry about this product?

Go here

Product Information

Autoantibodies staining the nuclei or the perinuclear zone of neutrophils by indirect immunofluorescence are referred to as pANCA whereas those giving a clear cytoplasmic fluorescence are referred to as cANCA. The antigen recognised by most cANCA sera has been identified as proteinase 3 (also known as myeloblastin, p29 or AGP7).

Autoantibodies to proteinase 3 are found in the sera of patients with active Wegener's granulomatosis and less often in other types of systemic vasculitis including microscopic polyangiitis, idiopathic crescentic glomerulonephritis, Churg-Strauss syndrome and polyarteritis nodosa.

Proteinase 3 (PR3) is a serine proteinase with proteolytic activity towards a range of substrates. The protein has been described as having antibiotic and growth-promoting properties but has been noted to causing emphysema when administered by tracheal insufflation.

Proteinase 3 cDNA has been cloned and sequenced, revealing the protein to be a basic 25 kDa glycoprotein of 228 amino acids. The protein reveals a triplet of bands in the range 29-32 kDa when subjected to denaturing SDS-electrophoresis, probably caused by differing degrees of glycosylation. Although proteinase 3 shows significant homology to elastase and cathepsin G, cANCA sera do not cross react with these serine proteases.

Autoantibodies to PR3 appear to recognise conformational epitopes and have been reported to interfere with inactivation of the enzyme by α1-antitrypsin and to also inhibit proteolytic activity itself.

Clinical Indications

Vasculitic Diseases
Wegener’s Granulomatosis

Certificate of Analysis

Please log in to view certificates of analysis for this item

References

  1. Davies, D.J. et al. (1982) Br. Med. J. 285, 606
  2. Wiik, A. et al. (1994) Man. Biol. Markers of Dis. (Kluwer Acad.Publ.) A9:1-14
  3. Ludemann, J. et al. (1990) J. Exp. Med. 171, 357
  4. Jenne, D.E. et al. (1990) Nature 346, 520
  5. Gupta, S.K. (1990) Blood, 76, 2162
  6. Wiik, A. (1995) Semin. Clin. Immunol. 9, 5
  7. Kallenberg, C.G.M. et al. (1994) Kidney Int. 46, 1
  8. Kam, C.M. et al. (1992) FEBS Lett. 297, 119
  9. Dolman, K.M. et al. (1992) FEBS Lett. 314, 117
  10. Campanelli, D. et al. (1990) J. Exp. Med. 172, 1709
  11. Bories, D. et al. (1989) Cell 59, 959
  12. Kao, R.C. et al. (1988) J. Clin. Invest. 82, 1963
  13. Wieslander, J. & Wiik, A. (1994) Man. Biol. Markers of Dis.(Kluwer Acad. Publ.) B1:1-9
  14. Goldschmeding, R. et al. (1989) J. Clin. Invest. 84, 1577
  15. Nassberger, L. et al. (1993) Autoimmunity 14, 259
  16. Bini, P. et al. (1992) J. Immunol. 149, 1409
  17. Van den Wiel, A. et al. (1992) Clin. Exp. Immunol. 90, 409
  18. Ludemann, J. et al. (1988) J. Immunol. Meth. 114, 167
  19. Daha, M.R. et al. (1990) Neth. J. Med. 36, 117
  20. Kallenberg, C.G.M. & Rasmussen, N. (1990) Neth. J. Med. 36,132
  21. Gaskin, G. et al. (1995) J. Immunol. Meth. 180, 25
  22. Stumann, L. & Wiik, A. (1997) J. Immunol. Meth. 206, 35
  23. Heegaard, N.H.H. et al. (1997) Anal. Biochem. 253, 259
  24. Hagen, E.C. et al. (1993) J. Immunol. Meth. 159,1
  25. Hagen, E.C. et al. (1996) J. Immunol. Meth. 196, 1

After a custom reagent?

Need to discuss specific protein requirements. Our team can help create tailored solutions to meet your diagnostic needs.